NEW YORK—Predicting genetic testing company Signal Genetics
recently announced it will acquire the assets of ChipDX LLC to add diagnostic
products in development for lung, breast and colon cancers.

Financial terms of the agreement have not been released.

Signal makes a prognostic test for multiple myeloma called
MyPRS Plus, and will use its sales team to bring ChipDX's products to market,
the company said. ChipDX's BreastGeneDX, ColonGeneDX and LungGeneDX products
are designed to determine patients' cancer risk levels.

"The acquisition of the intellectual property and patents of
ChipDX dramatically expands and enhances our oncology pipeline," Signal
Genetics CEO Joe Hernandez says. "The addition of ChipDX's bioinformatics
capabilities drastically reduces our time to market with novel molecular tests
designed to facilitate better patient outcomes at a lower cost profile."

Hernandez says the transaction "adds innovative intellectual
property, including patented prognostic tests for lung, breast and colon
cancers, as well as additional biologics expertise and a web-based interface to
Signal Genetics' oncology portfolio."

ChipDX is a privately held molecular diagnostics and
personalized medicine company based in New York. It was founded and is
currently led by Dr. Ryan VanLaar, who will join Signal Genetics as the head of
its Bioinformatics division.

VanLaar says teaming up with Signal Genetics provides his
company with a vehicle to ultimately commercialize its strong portfolio of
predictive molecular diagnostic tests.

"I look forward to leveraging the experience gained in the
development of ChipDX to help Signal Genetics achieve its goals, and ultimately
improve patient outcomes," he adds.

Hernandez explains that Signal Genetics' forte is the
development and commercialization of predictive and prognostic genomic tests
for the treatment of various types of cancer—and the acquisition of ChipDX
enhances and complements the company's product portfolio.

"This acquisition is part of our strategy to build on our
proprietary, algorithm-based prognostic and predictive genetic tests on the
market and in development to expand our oncology portfolio," Hernandez says.
"Our objective is to provide crucial services for doctors to identify best
course of treatment for individual patients in our areas of focus, which now
include myeloma, colon, breast, lung and prostate—areas that make up a large
global market."

With a solid footprint in oncology, ChipDX proved to be an
attractive acquisition because of its work in various types of cancer,
including most recently for its work on the BreastGeneDX prognostic test.

"We currently have two tests on the market and that are
covered by Medicare and private payers—MyPRS Plus, the only prognostic genomic
test for multiple myeloma on the market, and Previstage GCC, an innovative test
to determine if colon cancer is at an advanced stage and its likelihood of
recurrence," he says. "With this transaction, Signal acquired additional
diagnostic and prognostic tests in development for breast, colon and lung
cancers (as well as related patents) that we believe offer great promise for
cancer patients."

Signal Genetics will also acquire ChipDX's web-based
interface, which will be used to enhance Signal's physician web portal and
allow for remote interpretation of test algorithms.

Going forward, Hernandez says success of the acquisition
will be gauged by the driving adoption of these innovative tests over time.

"We think there is an undeniable need to identify high risk
patients early on to aggressively target cancers," he says. "Our acquisition of
ChipDX augments our clinically-driven bioinformatics capabilities, and will
help us to facilitate better patient outcomes and more appropriate use of
financial resources."